Form 4: Director Sells Recursion Pharmaceuticals Stock

Director Christopher Gibson has sold 40,000 shares of Recursion Pharmaceuticals Class A Common Stock for $3.10 per share, totaling $124,000, as part of a pre-arranged trading plan.

Summary

• Director Christopher Gibson reported a transaction involving Recursion Pharmaceuticals, Inc. (RXRX).
• On April 7, 2026, Gibson sold 40,000 shares of Class A Common Stock.
• The sale was executed at a price of $3.10 per share, resulting in a total transaction value of $124,000.
• This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025.
• Following the transaction, Gibson beneficially owns 906,556 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the sale was conducted under a pre-arranged trading plan, which is a common and accepted practice for insiders.

Negatives

• Director sold a significant number of shares (40,000) of Class A Common Stock.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a report of a past transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The execution of a Rule 10b5-1 plan indicates a pre-planned sale, often used by executives to diversify holdings or manage personal finances without triggering insider trading concerns.

Stakeholder Impact

• Shareholders may view insider selling as a negative signal, although the Rule 10b5-1 plan mitigates concerns about non-public information.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Sale, Recursion Pharmaceuticals, RXRX, Christopher Gibson, Rule 10b5-1, Class A Common Stock